<DOC>
	<DOCNO>NCT00002646</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Combining chemotherapy hormone therapy may kill tumor cell . Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use fenretinide may effective way prevent recurrence breast cancer . It yet know whether tamoxifen plus fenretinide effective tamoxifen alone breast cancer . PURPOSE : Randomized phase III trial compare effectiveness tamoxifen plus fenretinide tamoxifen alone treat postmenopausal woman stage II stage III breast cancer estrogen receptor positive and/or progesterone receptor positive .</brief_summary>
	<brief_title>Hormone Therapy Treating Postmenopausal Women With Receptor-Positive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease free survival overall survival postmenopausal woman stage II IIIA breast cancer treat tamoxifen ( TMX ) fenretinide ( HPR ) v TMX placebo . II . Gain wide experience use toxicity combine TMX/HPR patient . III . Obtain tumor tissue sample , feasible , patient future biologic study . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify participate institution , age ( 70 vs 70 ) , node dissection ( yes v ) , number involve node ( 0 vs 1-3 v 4 ) , number remove node ( 1-5 v 6 ) . All patient receive oral tamoxifen daily least 5 year , begin immediately randomization . Patients also receive either oral fenretinide oral placebo daily 5 year , begin within 2 week completion radiotherapy , within 2 week randomization , radiation . Patients follow treatment every 4 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 1,500 patient accrue study approximately 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Pathologic stage T13 , N12 , M0 No clinical pathologic T4 disease No primary tumor fix chest wall No axillary node fix chest wall neurovascular bundle No preoperative arm edema No clinical skin involvement ( microscopic focal dermal invasion dermal lymphatic involvement eligible ) No clinical N2 disease Modified radical mastectomy lumpectomy require prior entry Sentinel node biopsy allow Randomization require within 12 week definitive surgery Surgery date mastectomy axillary dissection lumpectomy No positive deep mastectomy margin Radiotherapy plan within 12 week follow axillary node dissection lumpectomy patient Synchronous bilateral breast cancer eligible If tumor least 2 cm , node involve If tumor least 2 cm , least 1 node must involve Both invasive primary receptorpositive Previously treat , noninvasive breast cancer eligible No prior invasive breast cancer No adenoid cystic , squamous , sarcomatous histology Hormone receptor status : Estrogen progesteronereceptor positive , i.e . : At least 10 fmole/mg cytosol protein ligandbinding assay OR Receptor positive immunocytochemistry PATIENT CHARACTERISTICS : Age : 65 OR Postmenopausal ineligible/inappropriate decline active node positive adjuvant study Sex : Female Menopausal status : Postmenopausal , define : At least 1 year since last menstrual period Hysterectomized bilateral oophorectomy Hysterectomized 1 ovary remain either : Over 60 FSH postmenopausal range Not surgically castrate , 60 , HRT FSH elevate 2 week HRT discontinue Performance status : Not specify Life expectancy : At least 7 year except breast cancer Hematopoietic : WBC great 3,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST le 2 time normal Renal : Creatinine great 2.0 mg/dL BUN great 25.0 mg/dL Other : No extensive macular degeneration exam within 1 year entry , e.g . : No exudative atrophic macular lesion reduce correct vision less 20/40 Health adequate protocol treatment No nutritional supplementation except single daily multivitamin No vitamin A supplement Gynecologic exam within past year require woman retain uterus No second malignancy within past 10 year except : Inactive nonmelanomatous skin cancer Carcinoma situ cervix Prior noninvasive contralateral breast cancer PRIOR CONCURRENT THERAPY : No prior chemotherapy hormonal therapy breast cancer except : Up 1 month tamoxifen start non participate physician At least 2 week since hormone replacement therapy No concurrent megestrol</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>